Share This

Related Topics News -

     
 Title only   |   Print    Next page > 
     
加科思-B於美國癌症研究協會年會披露兩藥物臨床前評估結果

2024-04-10T  
《公司業績》加科思全年虧損收窄至3.59億人民幣

2024-04-02T  
加科思確認各項業務運營一切正常

2024-03-06T  
加科思-B治療實體瘤新藥臨床試驗申請獲美國批准

2024-03-01T  
《大行報告》中金:國指及科指檢討結果料對聯通及同程影響正面 22隻股份或符納入港股通

2024-02-20T  
加科思自主研發抑制劑獲批三期臨床研究

2024-02-18T  
加科思-B(01167.HK)將於醫學研討會公布胰腺癌藥物臨床資料

2023-12-07T  
加科思-B公布肺癌聯合療法臨床數據 驗證具安全性及有效性

2023-10-24T  
《公司業績》加科思-B半年虧損擴大至1.66億元人民幣

2023-08-31T  
加科思抑制劑格來雷塞獲突破性治療藥物認定

2023-08-08T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.